Formulation Development
VistaGen Therapeutics Acquires Worldwide Rights to Develop & Commercialize First-in-Class Intranasally Administered Drug
VistaGen Therapeutics Inc. recently announced it has exercised its option to acquire from Pherin Pharmaceuticals, Inc. the exclusive license for worldwide rights to develop and commercialize PH10, a first-in-class, intranasally administered neuroactive steroid (a pherine), with rapid-onset antidepressant effects for treatment of major depressive disorder (MDD) demonstrated in a Phase 2a study
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study
VBI Vaccines Inc. recently announced the last subject has received the last vaccination in the PROTECT Phase 3 study of Sci-B-Vac, the company’s third-generation prophylactic hepatitis B vaccine.
Arcis Biotechnology & Teleflex Sign License Agreement
Arcis Biotechnology recently announced it has signed a technology access agreement with Teleflex Incorporated. Teleflex will harness Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology, which it believes will be disruptive, and is intended to empower clinicians and drive better patient outcomes.
Hovione Increases Production Capacity; One-Site-Shop Expands to Respond to Growing Demands
Hovione recently announced a plan to increase production capacity in oral dosage forms in Portugal to strengthen the integrated offering. New commercial-scale equipment for blending, tableting, and coating will complement existing development small-scale equipment.
Principia Achieves $10 Million in Additional Milestones
Principia Biopharma Inc. recently announced the achievement of $10 million in additional milestones related to successful development activities conducted by Principia as part of the…
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ
EyePoint Pharmaceuticals, Inc. recently announced the US FDA has approved YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment…
Krystal Biotech Announces Positive Interim Results
Krystal Biotech, Inc. recently announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103. Two adult Recessive Dystrophic Epidermolysis Bullosa (RDEB),…
Importance of Cell Cycle & Cellular Senescence in the Placenta Discovered
Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of…
Athenex & Xiangxue Life Sciences Announce Preliminary Study Results
Athenex, Inc. recently announced that preliminary results of pilot studies in China in which patients received T-cell receptor affinity enhancing specific T-cell therapy (TAEST) showed encouraging…
Sarepta & Lysogene Announce Exclusive License Agreement
Sarepta Therapeutics, Inc. recently announced it has signed a license agreement with Lysogene (FR0013233475 - LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting…
MeiraGTx Announces Acquisition of Vector Neurosciences
MeiraGTx Holdings Plc recently announced it has acquired Vector Neurosciences Inc. in an all-stock transaction. As a result of the acquisition, which was signed and…
Sitryx Launches With $30 Million to Develop Disease-Modifying Therapeutics
Sitryx recently announced it has closed its Series A financing round. The company, founded with seed funding from SV Health investors, raised a total of…
BioCorRx Announces Preliminary Agreement With VDM Biochemicals
BioCorRx Inc. recently announced the execution of a letter of intent (LOI) with VDM Biochemicals, Inc. (VDM), subject to execution of a definitive agreement, whereby…
Acquisitions Bolster PCI’s Global Position for Speed-to-Market
PCI Pharma Services’ presence at CPhI Worldwide 2018 (October 9-11, Madrid, Spain – Stand 3F10) highlighted considerable growth and expansion, including acquisition and integration of…
Amicus Therapeutics Enters Research & Development Collaboration
Amicus Therapeutics recently announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to…
Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
Wave Life Sciences Ltd. recently announced plans to design and advance stereopure oligonucleotide therapeutics for the potential treatment of rare, inherited eye diseases. Wave’s research…
Ziopharm & Precigen Redefine Relationships, Announce New License Agreement
Ziopharm Oncology, Inc. and Precigen, Inc. recently announced a new definitive license agreement to replace all existing agreements between the companies that will provide Ziopharm with certain exclusive and non-exclusive rights to technology controlled by Precigen, Inc.
Pacific Biosciences Announces a New Paradigm in DNA Sequencing
Pacific Biosciences of California, Inc. recently announced major enhancements to its Sequel System, including a new version (6.0) of its software, new consumable reagents (3.0) and a new SMRT Cell (1M v3).
STRATA Skin Sciences Announces Completion of a Clinical Study
STRATA Skin Sciences recently announced the completion of a multi-center clinical study investigating the efficiency and efficacy of its FDA cleared Multi-Micro Dose (MMD) diagnostic…
Orphazyme Reports Encouraging Arimoclomol Clinical Trial Top-Line Data
Orphazyme A/S recently announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease…
